Eli Lilly and Company
LLY
$732.41
$11.501.60%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 44.68% | 20.43% | 35.98% | 25.98% | 28.10% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 44.68% | 20.43% | 35.98% | 25.98% | 28.10% |
| Cost of Revenue | 34.44% | 16.70% | 20.07% | 2.88% | 15.50% |
| Gross Profit | 47.10% | 21.34% | 40.40% | 33.02% | 31.49% |
| SG&A Expenses | 27.58% | 17.53% | 10.67% | 12.41% | 16.73% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.56% | 15.64% | 15.24% | 15.01% | 20.93% |
| Operating Income | 81.57% | 28.49% | 88.95% | 59.53% | 44.65% |
| Income Before Tax | 100.84% | 271.82% | 68.38% | 65.79% | 19.67% |
| Income Tax Expenses | 97.09% | 27.55% | 68.93% | 58.66% | 101.07% |
| Earnings from Continuing Operations | 101.39% | 1,790.42% | 68.27% | 66.77% | 13.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 101.39% | 1,790.42% | 68.27% | 66.77% | 13.01% |
| EBIT | 81.57% | 28.49% | 88.95% | 59.53% | 44.65% |
| EBITDA | 75.45% | 26.94% | 78.69% | 50.99% | 38.66% |
| EPS Basic | 101.57% | 1,787.93% | 68.05% | 66.81% | 13.10% |
| Normalized Basic EPS | 81.85% | 26.35% | 89.20% | 59.62% | 45.46% |
| EPS Diluted | 101.85% | 1,777.12% | 68.21% | 66.44% | 13.01% |
| Normalized Diluted EPS | 81.85% | 25.79% | 89.14% | 59.50% | 45.46% |
| Average Basic Shares Outstanding | -0.09% | 0.13% | 0.13% | -0.02% | -0.08% |
| Average Diluted Shares Outstanding | -0.09% | 0.58% | 0.17% | 0.06% | -0.08% |
| Dividend Per Share | 15.04% | 15.04% | 15.04% | 15.04% | 15.31% |
| Payout Ratio | -0.43% | 1.07% | -0.32% | -0.31% | 0.02% |
